Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators

Wilschanski, 2007, Patterns of GI disease in adulthood associated with mutations in the CFTR gene, Gut, 56, 1153, 10.1136/gut.2004.062786 Corriveau, 2018, Cystic fibrosis survival: the changing epidemiology, Curr Opin Pulm Med, 24, 574, 10.1097/MCP.0000000000000520 Elborn, 2016, Cystic fibrosis, Lancet, 388, 2519, 10.1016/S0140-6736(16)00576-6 Balfour-Lynn, 2020, CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis, Paediatr Respir Rev Shteinberg, 2020, Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease, Eur Respir Rev, 29, 190112, 10.1183/16000617.0112-2019 Maqbool, 2017, Cystic Fibrosis and gastroesophageal reflux disease, J Cyst Fibros, 16, S2, 10.1016/j.jcf.2017.07.007 Mousa, 2012, Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management, Curr Gastroenterol Rep, 14, 226, 10.1007/s11894-012-0261-9 Goralski, 2013, Eosinophilic esophagitis in cystic fibrosis: a case series and review of the literature, J Cyst Fibros, 12, 9, 10.1016/j.jcf.2012.09.002 Haller, 2014, Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications, J Gastroenterol Hepatol, 29, 1344, 10.1111/jgh.12546 Brecelj, 2016, Morphological and functional assessment of oesophageal mucosa integrity in children with cystic fibrosis, J Pediatr Gastroenterol Nutr, 62, 757, 10.1097/MPG.0000000000001131 Mackey, 2004, High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report, BMC Pediatr, 4, 10.1186/1471-2431-4-19 Ayoub, 2017, Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis, Gastroenterol Res, 10, 288, 10.14740/gr917w DiMango, 2014, Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis, BMC Pulm Med, 14, 10.1186/1471-2466-14-21 McCrory, 2018, Use and incidence of adverse effects of proton pump inhibitors in patients with cystic fibrosis, Pharmacotherapy, 38, 725, 10.1002/phar.2125 Boesch, 2007, Outcomes of fundoplication in children with cystic fibrosis, J Pediatr Surg, 42, 1341, 10.1016/j.jpedsurg.2007.03.030 Fathi, 2009, Cough in adult cystic fibrosis: diagnosis and response to fundoplication, Cough, 5, 1, 10.1186/1745-9974-5-1 Shah, 2013, The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients, Pediatr Pulmonol., 48, 1181, 10.1002/ppul.22697 Zeybel, 2017, Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation, J Cyst Fibros, 16, 124, 10.1016/j.jcf.2016.07.004 Gibson-Corley, 2016, Pancreatic pathophysiology in cystic fibrosis, J Pathol, 238, 311, 10.1002/path.4634 Marson, 2018, Pancreatic insufficiency in cystic fibrosis: influence of inflammatory response genes, Pancreas, 47, 99, 10.1097/MPA.0000000000000963 Vanga, 2018, Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis, Clin Gastroenterol Hepatol, 16, 10.1016/j.cgh.2018.01.027 Turck, 2016, ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis, Clin Nutr, 35, 557, 10.1016/j.clnu.2016.03.004 Gomez-Pastrana, 2019, Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation, An Pediatr (Barc), 90, 148, 10.1016/j.anpedi.2018.05.022 Hamilton, 2019, Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor, Pediatr Pulmonol, 54, 1654, 10.1002/ppul.24454 Megalaa, 2019, Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use, Pediatr Pulmonol, 54, E16, 10.1002/ppul.24353 McNamara, 2019, Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study, Lancet Respir Med, 7, 325, 10.1016/S2213-2600(18)30460-0 Rosenfeld, 2019, An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5years (KLIMB), J Cyst Fibros, 18, 838, 10.1016/j.jcf.2019.03.009 Rosenfeld, 2018, Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study, Lancet Respir Med, 6, 545, 10.1016/S2213-2600(18)30202-9 Davies, 2016, Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study, Lancet Respir Med, 4, 107, 10.1016/S2213-2600(15)00545-7 Nichols, 2020, Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor, Paediatr Respir Rev, 35, 99 Freeman, 2017, Pancreatitis and pancreatic cystosis in cystic fibrosis, J Cyst Fibros, 16, S79, 10.1016/j.jcf.2017.07.004 Akshintala, 2019, Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis, Pancreatology, 19, 1023, 10.1016/j.pan.2019.09.014 Carrion, 2018, Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series, J Pediatr Gastroenterol Nutr, 66, 451, 10.1097/MPG.0000000000001788 Cohn, 1993, Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells, Gastroenterology, 105, 1857, 10.1016/0016-5085(93)91085-V Feranchak, 2004, Hepatobiliary complications of cystic fibrosis, Curr Gastroenterol Rep, 6, 231, 10.1007/s11894-004-0013-6 Debray, 2019, Modifier genes in cystic fibrosis-related liver disease, Curr Opin Gastroenterol, 35, 88, 10.1097/MOG.0000000000000508 Leung, 2017, Cystic fibrosis-related cirrhosis, J Cyst Fibros, 16, S50, 10.1016/j.jcf.2017.07.002 Karnsakul, 2020, A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease, J Cyst Fibros, 19, 546, 10.1016/j.jcf.2020.05.002 Alexopoulou, 2018, Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease, Scand J Gastroenterol, 53, 1547, 10.1080/00365521.2018.1534986 Stonebraker, 2016, Features of severe liver disease with portal hypertension in patients with cystic fibrosis, Clin Gastroenterol Hepatol, 14, 1207, 10.1016/j.cgh.2016.03.041 Leung, 2015, Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease, Hepatology, 62, 1576, 10.1002/hep.28016 Lam, 2019, Transient elastography in the evaluation of cystic fibrosis-associated liver disease: systematic review and meta-analysis, J Can Assoc Gastroenterol., 2, 71, 10.1093/jcag/gwy029 Debray, 2011, Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease, J Cyst Fibros, 10, S29, 10.1016/S1569-1993(11)60006-4 Palaniappan, 2017, Interventions for preventing and managing advanced liver disease in cystic fibrosis, Cochrane Database Syst Rev, 8 Cheng, 2017, Ursodeoxycholic acid for cystic fibrosis-related liver disease, Cochrane Database Syst Rev, 9 Cystic Fibrosis Agents. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD) 2012. Chaudary, 2018, Triplet CFTR modulators: future prospects for treatment of cystic fibrosis, Ther Clin Risk Manage, 14, 2375, 10.2147/TCRM.S147164 Safirstein, 2020, Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis, J Cyst Fibros Kutney, 2019, Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients, World J Hepatol, 11, 761, 10.4254/wjh.v11.i12.761 Hayes, 2015, Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy, J Pediatr Gastroenterol Nutr, 60, 578, 10.1097/MPG.0000000000000765 van de Peppel, 2019, IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation, J Cyst Fibros, 18, 286, 10.1016/j.jcf.2018.09.001 Sathe, 2017, Meconium ileus in cystic fibrosis, J Cyst Fibros, 16, S32, 10.1016/j.jcf.2017.06.007 Marson, 2018, Disease-modifying genetic factors in cystic fibrosis, Curr Opin Pulm Med, 24, 296, 10.1097/MCP.0000000000000479 Mentessidou, 2018, Long-term intestinal obstruction sequelae and growth in children with cystic fibrosis operated for meconium ileus: expectancies and surprises, J Pediatr Surg, 53, 1504, 10.1016/j.jpedsurg.2017.11.040 Houwen, 2010, Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS, J Pediatr Gastroenterol Nutr, 50, 38, 10.1097/MPG.0b013e3181a6e01d Green, 2018, Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis, Cochrane Database Syst Rev, 6 Groves, 2017, Question 8: How should distal intestinal obstruction syndrome [DIOS]. be managed?, Paediatr Respir Rev, 21, 68 Green, 2018, Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis, Cochrane Database Syst Rev, 8 Munck, 2016, International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome, J Cyst Fibros, 15, 531, 10.1016/j.jcf.2016.02.002 Walker, 2019, A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11years with cystic fibrosis, J Cyst Fibros, 18, 708, 10.1016/j.jcf.2019.06.009 FitzSimmons, 1997, High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis, N Engl J Med, 336, 1283, 10.1056/NEJM199705013361803 Smyth, 1994, Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes, Lancet, 343, 85, 10.1016/S0140-6736(94)90817-6 Waters, 1998, Cystic fibrosis with fibrosing colonopathy in the absence of pancreatic enzymes, Pediatr Dev Pathol, 1, 74, 10.1007/s100249900009 Mack, 2004, Fibrosing colonopathy in an adult cystic fibrosis patient after discontinuing pancreatic enzyme therapy, South Med J, 97, 901, 10.1097/01.SMJ.0000129939.14179.FE Serban, 2002, Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation, J Pediatr Gastroenterol Nutr, 35, 356, 10.1097/00005176-200209000-00022 Shields, 1991, Appendicitis in cystic fibrosis, Arch Dis Child, 66, 307, 10.1136/adc.66.3.307 Chaudry, 2006, Abdominal manifestations of cystic fibrosis in children, Pediatr Radiol, 36, 233, 10.1007/s00247-005-0049-2 Robertson, 2006, Review of the abdominal manifestations of cystic fibrosis in the adult patient, Radiographics, 26, 679, 10.1148/rg.263055101 Chaun, 2001, Colonic disorders in adult cystic fibrosis, Can J Gastroenterol, 15, 586, 10.1155/2001/745361 Zempsky, 1988, The cause of rectal prolapse in children, Am J Dis Child, 142, 338 Zhang, 2020, The cross-talk between gut microbiota and lungs in common lung diseases, Front Microbiol, 11, 301, 10.3389/fmicb.2020.00301 Anand, 2018, Diet, microbiota and gut-lung connection, Front Microbiol, 9, 2147, 10.3389/fmicb.2018.02147 Coffey, 2019, Gut microbiota in children with cystic fibrosis: a taxonomic and functional dysbiosis, Sci Rep, 9, 10.1038/s41598-019-55028-7 de Freitas MB, Moreira EAM, Tomio C, Moreno YMF, Daltoe FP, Barbosa E, et al. Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis. PLoS One. 2018;13(6):e0198457. Nielsen, 2016, Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis, Sci Rep, 6, 10.1038/srep24857 Kristensen, 2020, Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment, J Cyst Fibros, 19, 553, 10.1016/j.jcf.2020.04.007 Loman, 2020, Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis, Pediatr Pulmonol, 55, 1661, 10.1002/ppul.24766 Meeker SM, Mears KS, Sangwan N, Brittnacher MJ, Weiss EJ, Treuting PM, et al. CFTR dysregulation drives active selection of the gut microbiome. PLoS Pathog. 2020;16(1):e1008251. Vernocchi P, Del Chierico F, Russo A, Majo F, Rossitto M, Valerio M, et al. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS One. 2018;13(12):e0208171. Li L, Somerset S. Associations between flavonoid intakes and gut microbiota in a group of adults with cystic fibrosis. Nutrients. 2018;10(9). Burke, 2017, The altered gut microbiota in adults with cystic fibrosis, BMC Microbiol, 17, 58, 10.1186/s12866-017-0968-8 Schnapp, 2019, Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation, J Pediatr Gastroenterol Nutr, 68, 282, 10.1097/MPG.0000000000002197 Coffey MJ, Low I, Stelzer-Braid S, Wemheuer B, Garg M, Thomas T, et al. The intestinal virome in children with cystic fibrosis differs from healthy controls. PLoS One. 2020;15(5):e0233557. Miragoli, 2017, Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota, FEMS Microbiol Ecol, 93, 10.1093/femsec/fiw230 Neri, 2019, Systematic review of probiotics for cystic fibrosis patients: moving forward, J Pediatr Gastroenterol Nutr, 68, 394, 10.1097/MPG.0000000000002185 Nikniaz, 2017, Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials, World J Pediatr, 13, 307, 10.1007/s12519-017-0033-6 Kanhere M, He J, Chassaing B, Ziegler TR, Alvarez JA, Ivie EA, et al. Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. J Clin Endocrinol Metab. 2018;103(2):564-74. Vernocchi P, Del Chierico F, Quagliariello A, Ercolini D, Lucidi V, Putignani L. A Metagenomic and in silico functional prediction of gut microbiota profiles may concur in discovering new cystic fibrosis patient-targeted probiotics. Nutrients. 2017;9(12). Ooi, 2018, Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation, Sci Rep, 8, 10.1038/s41598-018-36364-6 Safe, 2016, Resolution of intestinal histopathology changes in cystic fibrosis after treatment with ivacaftor, Ann Am Thorac Soc, 13, 297, 10.1513/AnnalsATS.201510-669LE Stallings, 2018, Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations, J Pediatr, 201, 10.1016/j.jpeds.2018.05.018 Yamada, 2018, Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis, Lancet Oncol, 19, 758, 10.1016/S1470-2045(18)30188-8 Neglia, 1995, The risk of cancer among patients with cystic fibrosis, N Engl J Med, 332, 494, 10.1056/NEJM199502233320803 Hou, 2016, Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers, World J Gastrointest Oncol, 8, 282, 10.4251/wjgo.v8.i3.282 Dayama, 2020, Interactions between the gut microbiome and host gene regulation in cystic fibrosis, Genome Med, 12, 10.1186/s13073-020-0710-2 Hadjiliadis, 2018, Cystic fibrosis colorectal cancer screening consensus recommendations, Gastroenterology, 154, 736, 10.1053/j.gastro.2017.12.012 Gini, 2018, Cost effectiveness of screening individuals with cystic fibrosis for colorectal cancer, Gastroenterology, 154, 556, 10.1053/j.gastro.2017.10.036 Colombo, 1996, Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial, Hepatology, 23, 1484, 10.1002/hep.510230627 Lepage, 1997, Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis, J Pediatr, 130, 52, 10.1016/S0022-3476(97)70310-X Merli, 1994, Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial, J Pediatr Gastroenterol Nutr, 19, 198, 10.1097/00005176-199408000-00010 O'Brien, 1996, Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease, Eur J Gastroenterol Hepatol, 8, 477